ADARx Posts $901M Cash Pile, Says Funding Lasts Into 2030
ADRX sits 19% above its 52-week low of $12.5.
Summary
ADARx ended September with $901.0M in cash, equivalents and short-term investments, a balance that excludes roughly $62.3M in net proceeds received October 1. Management says that funds operations into 2030, which takes near-term financing risk off the table for a company that just came public in September. The quarter itself showed the spending ramp: net loss widened to $28.1M from $17.9M a year earlier, R&D rose to $26.7M from $19.4M, and collaboration revenue tied to the AbbVie agreement was just $2.2M versus $1.6M. The cash position traces back to the $446.3M IPO and $89.3M AbbVie private placement closed in late September, plus the underwriters' full exercise of their option. Onvuzosiran also picked up Fast Track designation for HAE, though no new trial data or approval timeline came with it.
At the time of this announcement, ADRX was trading at $14.91 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $1.7B. The 52-week trading range was $12.50 to $23.21. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: Wiseek News.